Immune checkpoint blockade (CP), which limits inhibitory pathways on CD8+ and CD4+ tumor-infiltrating lymphocytes (TILs), has demonstrated unparalleled clinical success in a wide variety of cancer types. Here, CD8A is linked to neoplasm.